Infliximab vs. Adalimumab for Crohn's disease

Aliment Pharmacol Ther. 2008 Nov 15;28(10):1265-6; author reply 1266-7. doi: 10.1111/j.1365-2036.2008.03829.x.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Humanized
  • Cost-Benefit Analysis
  • Crohn Disease / drug therapy*
  • Humans
  • Infliximab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Infliximab
  • Adalimumab